Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Viking Therapeutics (VKTX), a midcap biotech, has experienced significant stock price fluctuations following the release of its latest data. Despite meeting or exceeding expectations, the stock has seen a notable dip, dropping 13% as investors react to mixed signals. Analysts from JP Morgan and Truist have expressed confidence in VKTX's performance, highlighting its strong safety profile compared to competitors. The CEO is expected to provide updates on manufacturing by the end of the year, with a phase 3 meeting and Truist conference anticipated to offer further insights. However, concerns about manufacturing constraints and the timing of future catalysts have contributed to the volatility.
AstraZeneca stated on its official website Tuesday that it will fully cooperate with Chinese authorities if requested, in response to the investigation of its China-based executive. The company also affirmed that it will continue to deliver its life-changing medicines to patients… https://t.co/NZWGJxMbnD
AstraZeneca Falls Most Since 2020 as China Probe Fears Mount https://t.co/wrA2kWDpAK
$VKTX All this nonsense about manufacturing constraints is BS thesis used by short sellers and naysayers all year long Next year imagine when they run the trial using dual GLP/GIP at low doses maybe 40 to 60 mg ++++ dual Amylin agonist Weight loss will be significantly higher…
